scholarly journals Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy

2015 ◽  
Vol 6 (4) ◽  
pp. 495-507 ◽  
Author(s):  
Jason P. Gordon ◽  
Marc Evans ◽  
Jorge Puelles ◽  
Philip C. McEwan
Keyword(s):  
Type 2 Diabetes ◽  
Weight Gain ◽  
Combination Therapy ◽  
Diabetes Patients

Low plasma lactate concentration as a biomarker of an incompetent brain-pull: A risk factor for weight gain in type 2 diabetes patients

2010 ◽  
Vol 35 (9) ◽  
pp. 1287-1293 ◽  
Author(s):  
Regina van Dyken ◽  
Christian Hubold ◽  
Sonja Meier ◽  
Britta Hitze ◽  
Aja Marxsen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Risk Factor ◽  
Weight Gain ◽  
Lactate Concentration ◽  
Plasma Lactate ◽  
Plasma Lactate Concentration ◽  
Diabetes Patients

scholarly journals The Effect Of Diet Composition On Weight Gain in Obese, Type 2 Diabetes Patients Receiving Intensive Insulin Therapy

2015 ◽  
Vol 6 (2) ◽  
pp. 111-116
Author(s):  
Roland Villareal
Keyword(s):  
Type 2 Diabetes ◽  
Weight Gain ◽  
Insulin Therapy ◽  
Intensive Insulin Therapy ◽  
Diet Composition ◽  
High Carbohydrate ◽  
Total Calorie ◽  
Mufa Diet ◽  
Diabetes Patients

This study was conducted to contribute to the limiting existing body of literature about diet and prevention of weight gain when administering intensive insulin therapy.  The effects of a high- monounsaturated fatty acid (MUFA) diet compared with a conventional diabetic diet have not been studied in insulin treated patients.  A growing body of evidence assessed that diets rich in high-MUFA foods had similar glycemic results, as do low-fat, high carbohydrate diets.  However, a high-MUFA diet did not raise triglycerides as suspected.  Ros (2003) stated that high-MUFA energy controlled diets do not promote weight gain and are more acceptable for weight loss and/or maintenance. A MUFA diet can be used as an alternate to the conventional American Diabetic Association (ADA) diet when managing obese type 2 diabetes patients treated with intensive insulin therapy.  Dietary restriction to 1600 calories in diabetes patients on intensive insulin therapy decreased the A1C value by 1.3 points in the ADA group and 1.5 points in the MUFA group without weight gain and without additional insulin required.  In conclusion the total calorie count was more important for preventing weight gain and reducing the A1C in patients on intensive insulin therapy than was dietary composition.

The effects of pemafibrate in Japanese patients with type 2 diabetes receiving HMG-CoA reductase inhibitors

2020 ◽  
Vol 20 ◽  
Author(s):  
Masataka Kusunoki ◽  
Takahiko Sakazaki ◽  
Kazuhiko Tsutsumi ◽  
Tetsuro Miyata ◽  
Yoshiharu Oshida
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Hepatic Dysfunction ◽  
Combination Group ◽  
Hmg Coa Reductase ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase ◽  
Diabetes Patients

Objective: The combination therapy of HMG-CoA reductase inhibitors (statins), which are anti-hyperlipidemia agents, and fibrates may increase the risk of hepatic dysfunction and myopathy, so this combination required careful administration for patients. In the present study, we evaluated the effects of combination therapy of pemafibrate, a novel fibrate and statins. Methods: We administered pemafibrate for 6 months as an add-on to statin therapy in 27 type 2 diabetes patients with dyslipidemia already receiving statins for 6 months (combination group), and examined the efficacy and safety of the combination therapy in comparison with a pemafibrate monotherapy group. Results: In the combination group, decrease in serum total cholesterol levels was observed after 6 months of pemafibrate treatment compared to baseline, along with increase in HDL-cholesterol. While serum triglyceride level reduced, HbA1c level was elevated in both the groups. Serum creatinine kinase level, which is an indicator of myopathy, was lowered in the combination group. In addition, decrease in -glutamyl transpeptidase, a parameter of hepatic dysfunction, was observed in the combination group. Conclusion: The statin-pemafibrate combination therapy in type 2 diabetes patients with dyslipidemia improved lipid metabolism safely without increasing the risk of hepatic dysfunction and myopathy.

scholarly journals Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide

2013 ◽  
Vol 5 (4) ◽  
pp. 400-409 ◽  
Author(s):  
Kyoko Kudo-Fujimaki ◽  
Takahisa Hirose ◽  
Tomoaki Yoshihara ◽  
Fumihiko Sato ◽  
Yuki Someya ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Efficacy And Safety ◽  
Diabetes Patients

scholarly journals Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients

2012 ◽  
Vol 3 (6) ◽  
pp. 503-509 ◽  
Author(s):  
Akira Kubota ◽  
Hajime Maeda ◽  
Akira Kanamori ◽  
Kiyokazu Matoba ◽  
Yasuyuki Jin ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Efficacy And Safety ◽  
Diabetes Patients

scholarly journals What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019

2020 ◽  
Vol 23 (1) ◽  
pp. 106-110
Author(s):  
Marina V. Shestakova ◽  
Mikhail B. Antsiferov ◽  
Alexander S. Ametov ◽  
Gagik R. Galstyan ◽  
Tatiana Y. Demidova ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Combination Therapy ◽  
Glucose Lowering ◽  
Lowering Therapy ◽  
Clinical Benefits ◽  
Glucose Lowering Therapy ◽  
Diabetes Patients

According to key diabetic studies, the early use of metformin glucose lowering therapy is associated with a reduced risk of developing micro- and, in the long term, 10-year follow-up, macrovascular complications and cardiovascular mortality. Short-term studies results on combined glucose lowering therapy with metformin suggests that combination therapy can have several advantages on the one side from the effectiveness of glycemic control and on another side from positive effect on the development of complications of type 2 diabetes. The question of the start time of combined hypoglycemic therapy remains open. According to the results of recent large-scale studies, real world evidence data, careful glycemic control during the first year from the moment of diagnosis of type 2 diabetes is crucial for further management of the disease and slow the progression of complications. However, due to the fact that the clinical benefits of early combination therapy were not demonstrated in randomized clinical trials, this approach, despite the theoretical background, was not recommended for widespread use in international guidelines for the treatment diabetes patients. Russian algorithms on the treatment diabetes patients recommend combined glucose lowering therapy at the start of treatment at a HbA1c level of 1% higher than the target. A 5-year VERIFY study results were demonstrated long-term sustained glycemic control in combination with vildagliptin + metformin prescribed for native diabetes patients with relatively low HbA1c values, as well as the advantages of this approach in comparison with the standard strategy for phased intensification of monotherapy. The results of the VERIFY study provided a wealth of information to discuss early treatment intensification, the clinical benefits of this approach and a possible review of the treatment strategy for native diabetes patients.

Sign in / Sign up

Export Citation Format

Share Document